Bukwang Pharmaceutical IND

At a glance

Bukwang Pharmaceutical IND filed 38 disclosures in the last 12 months, including 3 earnings. The most recent key filing was on Oct 23: Operating profit ₩2.2B, up 120.7% YoY. Revenue ₩58B, up 21.2% YoY.

Revenue for 2025 was ₩201B, up 25.4% on 2024. Operating margin was 7.1% against 1% a year earlier. Debt was 40% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩105B and operating profit of ₩2.5B.

The 2025 annual report lists 650 employees with an average tenure of 10.3 years and average pay of ₩62.7M, #852 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩143.2M each on average. It paid ₩125 per common share in cash dividends. OCI홀딩스 주식회사 and related parties held 17.11% at year end.

From the 2025 annual report

Staff: 650 (432 men, 218 women), of whom 30 on fixed-term contracts. Total pay for the year: ₩40.7B. Directors and auditors: 6, paid ₩859.4M in total.

Dividends (common shares)

Largest shareholder

OCI홀딩스 주식회사 holds 17.11%; with 0 related parties the group holds 17.11% of common shares at year end (from 11.32% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary